Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring.
OBJECTIVE
To provide practical recommendations for monitoring patients both before and during treatment with atypical antipsychotics, to assist clinicians in implementing preventative measures against diabetes, and to establish baselines according to which clinicians should initiate diabetes treatment.


METHODS
A working group of Canadian specialists in psychiatry and endocrinology reviewed peer-reviewed clinical studies published in this area and other relevant papers and abstracts.


RESULTS
The reviewed studies further confirm that atypical antipsychotic medications are the most effective components in the medical management of many psychotic conditions; they also further emphasize the need to more stringently monitor and recognize diabetes risk factors inherent in these patients. Recommendations are based on a review of the available data, on expert opinion and consensus, and on current Canadian guidelines for the treatment of schizophrenia and management of diabetes.


CONCLUSIONS
Patients with psychiatric disorders, most particularly schizophrenia and mood disorders, have an increased risk for type 2 diabetes and should be screened frequently, especially when other risk factors are present. The resulting recommendations offer practical steps for effectively screening patients prior to and during treatment with atypical antipsychotics. They include (1) how to conduct an initial baseline assessment, (2) when and how to monitor blood glucose and lipid levels, and (3) how to educate patients regarding such lifestyle issues as nutrition, exercise, and diet.
Poulin
Marie-Josée
MJ
Centre Hospitalier Affilié Universitaire de Québec, Hôpital de l'Enfant-Jésus, Quebec. louise.croteau@cha.quebec.qc.ca
Cortese
Leonardo
L
Williams
Richard
R
Wine
Nina
N
McIntyre
Roger S
RS
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000175:diagnosis; D016903:Drug Monitoring; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000175:diagnosis; D001523:Mental Disorders / Q000188:drug therapy*; D010818:Practice Patterns, Physicians'; D011570:Psychiatry / Q000379:methods*
D014150:Antipsychotic Agents; D001786:Blood Glucose